<DOC>
	<DOCNO>NCT02823171</DOCNO>
	<brief_summary>A Phase 1 , Open-Label , Single-Dose , Randomized , 2-Period Crossover Study Assess Bioequivalence Two Pacritinib Drug Product Formulations ( Phase 3 Clinical Trial [ P3CT ] Formulation [ Reference ] Final Market Image [ FMI ] Formulation [ Test ] ) Following Oral Administration Healthy Subjects</brief_summary>
	<brief_title>To Assess Bioequivalence Two Pacritinib Drug Product Formulations FMI Formulation Following Oral Administration Healthy Subjects</brief_title>
	<detailed_description>This study Phase 1 , open-label , single-dose , randomize , 2-period , 2-treatment sequence crossover study determine bioequivalence pacritinib follow administration 400-mg dos P3CT ( Reference ) FMI ( Test ) formulation characterize PK pacritinib . Each subject receive 2 treatment ( 400-mg oral dose four 100-mg pacritinib P3CT [ reference ] formulation capsule 400-mg oral dose four 100-mg pacritinib FMI [ test ] formulation capsule ) 2-period crossover design . Each treatment administer monotherapy 1 2 treatment period . A 9-day washout separate 2 administration study medication . Subjects remain confined Clinical Research Unit ( CRU ) throughout study safety observation PK blood sample collection</detailed_description>
	<criteria>1. male female , age 18 55 year , inclusive , tobacco user ; 2. BMI range 18.0 32.0 kg/m2 , inclusive ; 3. good health , determine clinically significant finding medical history , physical examination , vital sign determine Investigator , consultation sponsor ; 4. normal 12lead ECG , ECG finding ( include RR , PR , QT interval ; QT interval correct use Fridericia 's formula [ QTcF ] ; QRS duration ; ventricular heart rate ) deem clinically significant Investigator , consultation Sponsor ; 5. clinical laboratory evaluation ( include clinical chemistry panel [ fast least 10 hour ] , CBC , UA ) within reference range test laboratory , unless deem clinically significant Investigator , consultation Sponsor ; laboratory value may confirm repeat ; 6. negative test select drug abuse ( include alcohol ) Screening Checkin ( Day 1 Period 1 ) ; 7. negative hepatitis panel ( include HBsAg antiHCV ) negative HIV antibody screen ; 8. female childbearing potential must pregnant lactating , must agree use 1 follow form contraception time sign informed consent 10 day prior Checkin ( Day 1 ) Period 1 30 day final dose administration : nonhormonal intrauterine device ( IUD ) spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ( eg , NuvaRing® ) ; diaphragm spermicide ; cervical cap spermicide ; male sexual partner agree use male condom spermicide ; sterile sexual partner ; abstinence . Oral , implantable , transdermal , injectable hormonal contraceptive may use time sign informed consent 10 day prior Checkin ( Day 1 ) Period 1 14 day final dose administration . For female , pregnancy test result must negative Screening Checkin ( Day 1 ) Period 1 . Females childbearing potential must postmenopausal least 1 year surgically sterile ( eg , tubal ligation , hysterectomy ) least 90 day ; 9. male surgically sterile ( ie , vasectomy , document medical record physician ) agree use , Checkin ( Day 1 ) Period 1 90 day follow Study Completion/ET , 1 follow approve method contraception : male condom spermicide ; sterile sexual partner ; use female sexual partner IUD spermicide , female condom spermicide , contraceptive sponge spermicide , intravaginal system , diaphragm spermicide , cervical cap spermicide , oral , implantable , transdermal , injectable contraceptive . Subjects must agree refrain sperm donation Checkin ( Day 1 ) Period 1 90 day follow Study Completion/ET ; 10. able comprehend willing sign Informed Consent Form ( ICF ) 1. prior ingestion pacritinib ; 2. history clinical manifestation clinically significant cardiovascular , pulmonary , hepatic ( eg , hepatitis ) , renal , hematologic , gastrointestinal ( eg , celiac disease , peptic ulcer , gastroesophageal reflux , inflammatory bowel disease ) , metabolic , allergic , dermatological , neurological , psychiatric disorder ( determined Investigator ; appendectomy cholecystectomy consider clinically significant event ) ; 3. significant abnormality liver function test ( alanine aminotransferase , aspartate aminotransferase , alkaline phosphatase &gt; 1.5 × upper limit normal [ ULN ] ; gammaglutamyl transferase &gt; 2 × ULN ; total bilirubin &gt; 1.3 × ULN ) kidney function test ( serum creatinine &gt; ULN ) consider clinically significant Investigator ; laboratory value may confirm repeat ; 4. history malignancy , except follow : cancer determine cured remission ≥5 year , curatively resect basal cell squamous cell skin cancer , cervical cancer situ , resect colonic polyp ; 5. history significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator consultation Sponsor ; 6. history stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug except appendectomy , cholecystectomy , hernia repair allow ; 7. history Gilbert 's Syndrome ; 8. history presence ECG QTcF &gt; 450 msec , factor increase risk QTc interval prolongation ( eg , heart failure , hypokalemia [ define serum potassium &lt; 3.0 mEq/L persistent refractory correction ] , family history long QT interval syndrome ) ; 9. history alcoholism drug addiction within 1 year prior Checkin ( Day 1 ) Period 1 ; 10. use tobacco nicotinecontaining product within 6 month prior Checkin ( Day 1 ) Period 1 entire study ; 11. consumption alcohol caffeinecontaining food beverages 72 hour prior Screening entire study ; 12. consumption grapefruitcontaining food beverage CYP3A4 inhibitor inducers 72 hour prior Screening entire study ; 13. subject refrain strenuous exercise 48 hour prior Checkin ( Day 1 ) Period 1 period confinement CRU otherwise maintain normal level physical activity throughout entire study ( ie , begin new exercise program participate unusually strenuous physical exertion ) ; 14. participation investigational study drug trial receipt investigational study drug occur within 5 halflives 30 day prior Checkin ( Day 1 ) Period 1 , whichever longer , entire study ; 15. female subject unable refrain use oral , implantable , injectable , transdermal hormonal contraceptive within 10 day prior Checkin ( Day 1 ) Period 1 time signing inform consent 14 day final dose administration ; 16. use prescription medication and/or product within 14 day prior Checkin ( Day 1 ) Period 1 entire study , unless deem acceptable Investigator , consultation Sponsor ; 17. use overthecounter , nonprescription medication ( include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation ) within 7 day prior Checkin ( Day 1 ) Period 1 entire study , unless deem acceptable Investigator , consultation Sponsor ; 18. poor peripheral venous access ; 19. donation blood 30 day prior Screening Study Completion/ET , inclusive , plasma 2 week prior Screening Study Completion/ET , inclusive ; 20. receipt blood product within 2 month prior Checkin ( Day 1 ) Period 1 ; 21. acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bioequivalence Study</keyword>
	<keyword>Healthy subject</keyword>
</DOC>